CYTONK-102 is under clinical development by CytoImmune Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CYTONK-102’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CYTONK-102 is under development for the treatment of relapsed and refractory non-small cell lung cancer (NSCLC). It is administered through intravenous route. The drug candidate comprises of umbilical cord blood derived NK cells genetically engineered to express chimeric antigen receptor (CAR). It acts by targeting PD-L1 (Programmed Cell Death 1 Ligand 1) and and interleukin 15 and is being developed based on TRACK-NK platform technology.
CytoImmune Therapeutics overview
CytoImmune Therapeutics., a clinical-stage biopharmaceutical company that engaged in commercializing novel cancer immunotherapy products. The company is headquartered in United States.
For a complete picture of CYTONK-102’s drug-specific PTSR and LoA scores, buy the report here.